ArticleBiology methods & protocols2025
Integrating multiple microRNA functional similarity networks for improved disease-microRNA association prediction.
Article in Biology methods & protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Computational Method Using Attribute-Aware Message Passing and Graph Convolutional Network for Potential miRNA-Disease Association Prediction.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) play a critical role in disease mechanisms, making the identification of disease-associated miRNAs essential for precision medicine. We propose a novel computational method, multiplex-heterogeneous network for MiRNA-disease associations (MHMDA), which integrates multiple miRNA functional similarity networks and a disease similarity network into a multiplex-heterogeneous network. This approach employs a tailored random walk with restart algorithm to predict disease-miRNA associations, leveraging the complementary information from experimentally validated and predicted miRNA-target interactions, as well as disease phenotypic similarities. Evaluated on the human microRNA disease database and miR2Disease datasets using leave-one-out cross-validation and 5-fold cross-validation, MHMDA demonstrates superior performance, achieving area under the receiver operating characteristic curve values of 0.938 and 0.913 on human microRNA disease database and miR2Disease, respectively, and outperforming existing methods. The integration of multiplex networks enhances prediction accuracy by capturing diverse miRNA functional relationships, which directly contributes to the high area under the receiver operating characteristic curve and area under the precision-recall curve values observed. Additionally, MHMDA's stability across parameter variations and disease contexts underscores its robustness and potential for real-world applications in identifying novel disease-miRNA associations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.